HomeCompareBPMC vs SCHD

BPMC vs SCHD: Dividend Comparison 2026

BPMC yields 1.54% · SCHD yields 3.46%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SCHD wins by $7.1K in total portfolio value
10 years
BPMC
BPMC
● Live price
1.54%
Share price
$129.46
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.9K
Annual income
$170.75
Full BPMC calculator →
SCHD
Schwab U.S. Dividend Equity ETF
● Live price
3.46%
Share price
$30.48
Annual div
$1.06
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.0K
Annual income
$425.95
Full SCHD calculator →

Portfolio growth — BPMC vs SCHD

📍 SCHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPMCSCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPMC + SCHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPMC pays
SCHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPMC
Annual income on $10K today (after 15% tax)
$131.31/yr
After 10yr DRIP, annual income (after tax)
$145.14/yr
SCHD
Annual income on $10K today (after 15% tax)
$294.40/yr
After 10yr DRIP, annual income (after tax)
$362.06/yr
At 15% tax rate, SCHD beats the other by $216.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPMC + SCHD for your $10,000?

BPMC: 50%SCHD: 50%
100% SCHD50/50100% BPMC
Portfolio after 10yr
$25.5K
Annual income
$298.34/yr
Blended yield
1.17%
📊

Analyst Conviction Gap

Where Wall Street is split right now

BPMC
No analyst data
Price Target
$113.07
-12.7% upside vs current
Range: $41.00 — $155.00
Altman Z
3.7
Piotroski
4/9
SCHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPMC buys
0
SCHD buys
0
No recent congressional trades found for BPMC or SCHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPMCSCHD
Forward yield1.54%3.46%
Annual dividend / share$2.00$1.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$21.9K$29.0K
Annual income after 10y$170.75$425.95
Total dividends collected$1.6K$3.9K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BPMC vs SCHD ($10,000, DRIP)

YearBPMC PortfolioBPMC Income/yrSCHD PortfolioSCHD Income/yrGap
1← crossover$10,854$154.49$11,226$346.36$372.00SCHD
2$11,771$156.72$12,572$357.38$801.00SCHD
3$12,754$158.83$14,046$367.84$1.3KSCHD
4$13,807$160.84$15,660$377.73$1.9KSCHD
5$14,937$162.73$17,425$387.07$2.5KSCHD
6$16,147$164.52$19,354$395.86$3.2KSCHD
7$17,443$166.22$21,461$404.13$4.0KSCHD
8$18,832$167.82$23,762$411.89$4.9KSCHD
9$20,320$169.33$26,272$419.15$6.0KSCHD
10$21,913$170.75$29,010$425.95$7.1KSCHD

BPMC vs SCHD: Complete Analysis 2026

BPMCStock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Full BPMC Calculator →

SCHDETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →
📬

Get this BPMC vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPMC vs JEPIBPMC vs OBPMC vs KOBPMC vs MAINBPMC vs VYMBPMC vs DGROBPMC vs VIGBPMC vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.